{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:45:18Z","timestamp":1790520318402,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["Special Program Metastases (21198)"],"award-info":[{"award-number":["Special Program Metastases (21198)"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41375-025-02855-5","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:04:26Z","timestamp":1769069066000},"page":"577-586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-915X","authenticated-orcid":false,"given":"Michela","family":"Ansuinelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6338-3112","authenticated-orcid":false,"given":"Nadia","family":"Peragine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4956-8911","authenticated-orcid":false,"given":"Maria Stefania","family":"De Propris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Puzzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Di Trani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Skert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6372-2623","authenticated-orcid":false,"given":"Roberto","family":"Cairoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3739-7502","authenticated-orcid":false,"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3052-7463","authenticated-orcid":false,"given":"Alessandra","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cerrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Vallisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Cardinali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Mul\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Chiaretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Guarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5021-3026","authenticated-orcid":false,"given":"Robin","family":"Fo\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"2855_CR1","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMra2113347","volume":"386","author":"R Fo\u00e0","year":"2022","unstructured":"Fo\u00e0 R, Chiaretti S. Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2022;386:2399\u2013411.","journal-title":"N Engl J Med"},{"key":"2855_CR2","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","volume":"109","author":"M Vignetti","year":"2007","unstructured":"Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell\u2019Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109:3676\u20138.","journal-title":"Blood"},{"key":"2855_CR3","doi-asserted-by":"publisher","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","volume":"118","author":"R Fo\u00e0","year":"2011","unstructured":"Fo\u00e0 R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118:6521\u20138.","journal-title":"Blood"},{"key":"2855_CR4","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3324\/haematol.2016.144535","volume":"101","author":"S Chiaretti","year":"2016","unstructured":"Chiaretti S, Vitale A, Vignetti M, Piciocchi A, Fazi P, Elia L, et al. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. Haematologica. 2016;101:1544\u201352.","journal-title":"Haematologica"},{"key":"2855_CR5","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.3324\/haematol.2020.260935","volume":"106","author":"S Chiaretti","year":"2021","unstructured":"Chiaretti S, Ansuinelli M, Vitale A, Elia L, Matarazzo M, Piciocchi A, et al. A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol. Haematologica. 2021;106:1828\u201338.","journal-title":"Haematologica"},{"key":"2855_CR6","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1182\/bloodadvances.2021004821","volume":"6","author":"G Martinelli","year":"2022","unstructured":"Martinelli G, Papayannidis C, Piciocchi A, Robustelli V, Soverini S, Terragna C, et al. INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. Blood Adv. 2022;6:1742\u201353.","journal-title":"Blood Adv"},{"key":"2855_CR7","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Fo\u00e0","year":"2020","unstructured":"Fo\u00e0 R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, et al. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383:1613\u201323.","journal-title":"N Engl J Med"},{"key":"2855_CR8","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.23.01075","volume":"42","author":"R Fo\u00e0","year":"2024","unstructured":"Fo\u00e0 R, Bassan R, Elia L, Piciocchi A, Soddu S, Messina M, et al. Long-term results of the dasatinib-blinatumomab protocol for adult philadelphia-positive ALL. J Clin Oncol. 2024;42:881\u20135.","journal-title":"J Clin Oncol"},{"key":"2855_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2023023152","volume":"145","author":"S Chiaretti","year":"2025","unstructured":"Chiaretti S, Fo\u00e0 R. How I treat adult Ph+ ALL. Blood. 2025;145:11\u20139.","journal-title":"Blood"},{"key":"2855_CR10","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMra2405573","volume":"392","author":"R Fo\u00e0","year":"2025","unstructured":"Fo\u00e0 R. Ph-positive acute lymphoblastic leukemia-25 years of progress. N Engl J Med. 2025;392:1941\u201352.","journal-title":"N Engl J Med"},{"key":"2855_CR11","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1182\/blood.2021011822","volume":"138","author":"MC Puzzolo","year":"2021","unstructured":"Puzzolo MC, Radice G, Peragine N, de Propris MS, Mariglia P, Vignetti M, et al. Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab. Blood. 2021;138:2290\u20133.","journal-title":"Blood"},{"key":"2855_CR12","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/cmi.2010.20","volume":"7","author":"YY Wan","year":"2010","unstructured":"Wan YY. Regulatory T cells: immune suppression and beyond. Cell Mol Immunol. 2010;7:204\u201310.","journal-title":"Cell Mol Immunol"},{"key":"2855_CR13","volume":"1","author":"BS Dwarakanath","year":"2018","unstructured":"Dwarakanath BS, Farooque A, Gupta S. Targeting regulatory T cells for improving cancer therapy: Challenges and prospects. Cancer Rep. 2018;1:e21105.","journal-title":"Cancer Rep"},{"key":"2855_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1182\/blood-2025-439","volume":"146","author":"S Chiaretti","year":"2025","unstructured":"Chiaretti S, Di Trani M, Skert C, Elia L, Almici G, Della Starza I, et al. First results of the phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult Ph+ acute lymphoblastic leukemia patients. Blood. 2025;146:439.","journal-title":"Blood"},{"key":"2855_CR15","first-page":"275","volume":"88","author":"L Elia","year":"2003","unstructured":"Elia L, Mancini M, Moleti L, Meloni G, Buffolino S, Krampera M, et al. A multiplex reverse transcriptase-polymerase chain reaction strategy for the diagnostic molecular screening of chimeric genes: a clinical evaluation on 170 patients with acute lymphoblastic leukemia. Haematologica. 2003;88:275\u20139.","journal-title":"Haematologica"},{"key":"2855_CR16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.leu.2404586","volume":"21","author":"VH van der Velden","year":"2007","unstructured":"van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21:604\u201311.","journal-title":"Leukemia"},{"key":"2855_CR17","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1038\/s41375-019-0413-0","volume":"33","author":"H Pfeifer","year":"2019","unstructured":"Pfeifer H, Cazzaniga G, van der Velden VHJ, Cayuela JM, Sch\u00e4fer B, Spinelli O, et al. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph\u2009+\u2009ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukemia. 2019;33:1910\u201322.","journal-title":"Leukemia"},{"key":"2855_CR18","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","volume":"22","author":"MA Cooper","year":"2001","unstructured":"Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633\u201340.","journal-title":"Trends Immunol"},{"key":"2855_CR19","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1200\/JCO.24.00272","volume":"42","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, Short NJ, Haddad FG, Jain N, Huang X, Montalban-Bravo G, et al. Results of the simultaneous combination of ponatinib and blinatumomab in Philadelphia chromosome-positive ALL. J Clin Oncol. 2024;42:4246\u201351.","journal-title":"J Clin Oncol"},{"key":"2855_CR20","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783\u201396.","journal-title":"N Engl J Med"},{"key":"2855_CR21","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/leu.2017.41","volume":"31","author":"J Duell","year":"2017","unstructured":"Duell J, Dittrich M, Bedke T, Mueller T, Eisele F, Rosenwald A, et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia. 2017;31:2181\u201390.","journal-title":"Leukemia"},{"key":"2855_CR22","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/leu.2009.46","volume":"23","author":"S Mustjoki","year":"2009","unstructured":"Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, et al. Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23:1398\u2013405.","journal-title":"Leukemia"},{"key":"2855_CR23","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1002\/cncr.29933","volume":"122","author":"CA Schiffer","year":"2016","unstructured":"Schiffer CA, Cortes JE, Hochhaus A, Saglio G, le Coutre P, Porkka K, et al. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Cancer. 2016;122:1398\u2013407.","journal-title":"Cancer"},{"key":"2855_CR24","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/ajh.21980","volume":"86","author":"SJ Lee","year":"2011","unstructured":"Lee SJ, Jung CW, Kim DY, Lee KH, Sohn SK, Kwak JY, et al. Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia. Am J Hematol. 2011;86:346\u201350.","journal-title":"Am J Hematol"},{"key":"2855_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.leukres.2018.01.010","volume":"66","author":"Y Najima","year":"2018","unstructured":"Najima Y, Yoshida C, Iriyama N, Fujisawa S, Wakita H, Chiba S, et al. Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study. Leuk Res. 2018;66:66\u201372.","journal-title":"Leuk Res"},{"key":"2855_CR26","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202301743R","volume":"38","author":"K Cao","year":"2024","unstructured":"Cao K, Wang X, Wang H, Xu C, Ma A, Zhang Y, et al. Phenotypic and functional exhaustion of circulating CD3+ CD56+ NKT-like cells in colorectal cancer patients. FASEB J. 2024;38:e23525.","journal-title":"FASEB J"},{"key":"2855_CR27","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/ajco.13723","volume":"18","author":"X Zeng","year":"2022","unstructured":"Zeng X, Yao D, Liu L, Zhang Y, Lai J, Zhong J, et al. Terminal differentiation of bone marrow NK cells and increased circulation of TIGIT+ NK cells may be related to poor outcome in acute myeloid leukemia. Asia Pac J Clin Oncol. 2022;18:456\u201364.","journal-title":"Asia Pac J Clin Oncol"},{"key":"2855_CR28","doi-asserted-by":"publisher","first-page":"e005061","DOI":"10.1136\/jitc-2022-005061","volume":"10","author":"C Lou","year":"2022","unstructured":"Lou C, Wu K, Shi J, Dai Z, Xu Q. N-cadherin protects oral cancer cells from NK cell killing in the circulation by inducing NK cell functional exhaustion via the KLRG1 receptor. J Immunother Cancer. 2022;10:e005061.","journal-title":"J Immunother Cancer"},{"key":"2855_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01714-7","volume":"22","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Chen S, Tang X, Peng Y, Jiang T, Zhang X, et al. The role of KLRG1: a novel biomarker and new therapeutic target. Cell Commun Signal. 2024;22:337.","journal-title":"Cell Commun Signal"},{"key":"2855_CR30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00262-025-04059-3","volume":"74","author":"C Xu","year":"2025","unstructured":"Xu C, Cao K, Ma A, Zheng M, Xu Y, Tang L. KLRG1 expression induces functional exhaustion of NK cells in colorectal cancer patients. Cancer Immunol Immunother. 2025;74:203.","journal-title":"Cancer Immunol Immunother"},{"key":"2855_CR31","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1128\/JVI.01085-12","volume":"87","author":"L Golden-Mason","year":"2013","unstructured":"Golden-Mason L, McMahan RH, Strong M, Reisdorph R, Mahaffey S, Palmer BE, et al. Galectin-9 functionally impairs natural killer cells in humans and mice. J Virol. 2013;87:4835\u201345.","journal-title":"J Virol"},{"key":"2855_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.816499","volume":"12","author":"O Venglar","year":"2022","unstructured":"Venglar O, Bago JR, Motais B, Hajek R, Jelinek T. Natural killer cells in the malignant niche of multiple myeloma. Front Immunol. 2022;12:816499.","journal-title":"Front Immunol"},{"key":"2855_CR33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.intimp.2018.09.016","volume":"64","author":"M Yin","year":"2018","unstructured":"Yin M, Di G, Bian M. Dysfunction of natural killer cells mediated by PD-1 and Tim-3 pathway in anaplastic thyroid cancer. Int Immunopharmacol. 2018;64:333\u20139.","journal-title":"Int Immunopharmacol"},{"key":"2855_CR34","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","volume":"44","author":"JH Esensten","year":"2016","unstructured":"Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 costimulation: from mechanism to therapy. Immunity. 2016;44:973\u201388.","journal-title":"Immunity"},{"key":"2855_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s43556-025-00267-6","volume":"6","author":"Z Yan","year":"2025","unstructured":"Yan Z, Wang C, Wu J, Wang J, Ma T. TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives. Mol Biomed. 2025;6:27.","journal-title":"Mol Biomed"},{"key":"2855_CR36","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/bjh.19104","volume":"203","author":"D Ocadlikova","year":"2023","unstructured":"Ocadlikova D, Lussana F, Fracchiolla N, Bonifacio M, Santoro L, Delia M, et al. Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study. Br J Haematol. 2023;203:637\u201350.","journal-title":"Br J Haematol"},{"key":"2855_CR37","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2015-06-649111","volume":"126","author":"G Zugmaier","year":"2015","unstructured":"Zugmaier G, G\u00f6kbuget N, Klinger M, Viardot A, Stelljes M, Neumann S, et al. Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood. 2015;126:2578\u201384.","journal-title":"Blood"},{"key":"2855_CR38","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522\u201331.","journal-title":"Blood"},{"key":"2855_CR39","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/ajh.27227","volume":"99","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Zugmaier G, Agrawal V, Mart\u00ednez-S\u00e1nchez P, Rif\u00f3n Roca JJ, Cassaday RD, et al. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Am J Hematol. 2024;99:586\u201395.","journal-title":"Am J Hematol"},{"key":"2855_CR40","first-page":"1177","volume":"110","author":"M Dragani","year":"2025","unstructured":"Dragani M, Ansuinelli M, Papayannidis C, Fracchiolla N, Cardinali V, Cedrone M, et al. Tyrosine kinase inhibitor discontinuation in nonallografted Philadelphia-positive acute lymphoblastic leukemia patients: a Campus ALL real-life study. Haematologica. 2025;110:1177\u201381.","journal-title":"Haematologica"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02855-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02855-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02855-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:38:06Z","timestamp":1772609886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02855-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2855"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02855-5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to disclose. The results of this study have been presented in part at the last ASH Congress: Ansuinelli M et al.,\n                      Blood\n                      2024;144 (Supplement 1):838.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}